Sangamo secures $50M upfront in neurodegenerative pact with Roche`s Genentech
Biogen and Novartis may have walked away from partnerships with Sangamo Therapeutics last year, but that hasn't stopped Roche from seeking out a pact with the biotech to work on intravenous genomic medicines for neurodegenerative diseases.
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Announces Data From Novel Proprietary Neurotropic AAV Capsid